Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma

SIMPLE SUMMARY: Immune check point inhibitors (ICPIs) are one of the treatment options for advanced hepatocellular carcinoma (HCC). No biomarker is currently available to upfront select patients to be addressed to one or another drug. We have tested a prospective series of patients with advanced HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannini, Catia, Suzzi, Fabrizia, Tovoli, Francesco, Bruccoleri, Mariangela, Marseglia, Mariarosaria, Alimenti, Eleonora, Fornari, Francesca, Iavarone, Massimo, Piscaglia, Fabio, Gramantieri, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045974/
https://www.ncbi.nlm.nih.gov/pubmed/36980547
http://dx.doi.org/10.3390/cancers15061661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045974/
https://www.ncbi.nlm.nih.gov/pubmed/36980547
http://dx.doi.org/10.3390/cancers15061661

Ejemplares similares